Christopher Benecchi
Corporate Officer/Principal at SAGE THERAPEUTICS, INC.
Net worth: 364 118 $ as of 30/03/2024
Profile
Christopher Benecchi is currently the Chief Business Officer at SAGE Therapeutics, Inc. Prior to his current position, he served as the Vice President & Global Head-Commercial Excellence at Alexion Pharmaceuticals, Inc. from 2019 to 2021.
Before that, he was the Global Launch Head-Commercial & Medical Affairs at UCB, Inc. from 2011 to 2019.
Mr. Benecchi holds an MBA from Duke University and completed his undergraduate studies at Colby College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0.03% | 12/02/2024 | 19,430 ( 0.03% ) | 364 118 $ | 30/03/2024 |
Christopher Benecchi active positions
| Companies | Position | Start |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Corporate Officer/Principal | 20/09/2021 |
Former positions of Christopher Benecchi
| Companies | Position | End |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 31/08/2021 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 31/07/2019 |
Training of Christopher Benecchi
| Duke University | Masters Business Admin |
| Colby College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SAGE THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
- Stock Market
- Insiders
- Christopher Benecchi
